Patients' Perception of Vitiligo Severity.


Journal

Acta dermato-venereologica
ISSN: 1651-2057
Titre abrégé: Acta Derm Venereol
Pays: Sweden
ID NLM: 0370310

Informations de publication

Date de publication:
28 06 2021
Historique:
pubmed: 7 5 2021
medline: 30 6 2021
entrez: 6 5 2021
Statut: epublish

Résumé

Identifying which factors contribute to vitiligo severity and determining their individual weight are important in the management of vitiligo. The aim of this study is to investigate the predictive variables concerning vitiligo severity as perceived by the patients. Based on a questionnaire, several factors that may contribute to the Patient Global Assessment (PtGA) of severity were investigated within a Belgian vitiligo population (n = 291). In addition, possible factors influencing vitiligo severity were scored and ranked. The strongest correlations with the PtGA of severity were found for impact, Dermatology Life Quality Index and disease extent. Based on multivariable regression analyses, 64.7% of PtGA of severity could be predicted by subjective and objective variables, while 32% could be explained by objective clinical features only. Patients considered lesion location, extent and disease activity as the most important contributing factors to severity. Vitiligo severity is determined by objective clinical features, but also, for a significant part, by the perceived impact of the disease.

Identifiants

pubmed: 33954797
doi: 10.2340/00015555-3823
pmc: PMC9380269
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

adv00481

Références

J Dermatol. 2013 May;40(5):344-54
pubmed: 23441960
J Invest Dermatol. 2016 Jan;136(1):52-8
pubmed: 26763423
J Am Acad Dermatol. 2017 Oct;77(4):675-682.e1
pubmed: 28823882
J Invest Dermatol. 2016 May;136(5):978-984
pubmed: 26827762
Am J Clin Dermatol. 2017 Dec;18(6):733-744
pubmed: 28577207
Dermatol Ther. 2018 May;31(3):e12589
pubmed: 29512290
Lancet. 2020 Jul 11;396(10244):110-120
pubmed: 32653055
J Am Acad Dermatol. 2019 Nov;81(5):1107-1114
pubmed: 30763647
Health Qual Life Outcomes. 2016 Jun 07;14:86
pubmed: 27267598
Lancet. 2015 Jul 4;386(9988):74-84
pubmed: 25596811
Arch Dermatol. 2004 Jun;140(6):677-83
pubmed: 15210457
J Am Acad Dermatol. 2017 Mar;76(3):464-471
pubmed: 27887798
Br J Dermatol. 2008 Aug;159(2):351-9
pubmed: 18565189
J Eur Acad Dermatol Venereol. 2021 Jan;35(1):216-221
pubmed: 32452565
J Eur Acad Dermatol Venereol. 2019 Jan;33(1):191-197
pubmed: 30242917
Pigment Cell Res. 2007 Feb;20(1):27-35
pubmed: 17250545

Auteurs

Nanja van Geel (N)

Department of Dermatology, Ghent University Hospital, BE-9000 Gent, Belgium. E-mail: Nanja.vanGeel@UGent.be.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH